Steed Lab
banner
steedlab.bsky.social
Steed Lab
@steedlab.bsky.social
We are an undergraduate research group led by Ryan Steed at the University of North Carolina Asheville focused on studying the function and inhibition of ATP synthase, a biomolecular machine fundamental to how life uses energy.
We just published a paper with @wolfelab.bsky.social on a class of pyridine molecules that inhibit the ATP synthase of pathogenic Acinetobacter baumannii. Congrats to all of our UNCA undergraduate co-authors and high school co-authors from @ncssm-morganton.bsky.social!
pubs.acs.org/doi/10.1021/...
Synthesis and Evaluation of Pyridine-Based Antibacterial Agents that Inhibit ATP Synthase in Acinetobacter baumannii
Multidrug resistant Acinetobacter baumannii (MDR AB) is a growing global health threat due to rising infection rates and lack of treatment options. Specifically, like other Gram-negative pathogens, MDR AB employs a suite of robust cellular resistance mechanisms, including reduced penetration of the outer membrane, increased efflux, target modification, and others, that greatly impede antibiotic activity even for antibiotics of last resort like colistin and tigecycline. Bacterial bioenergetics are an under-explored antibiotic target and can be selectively exploited, as demonstrated by the success of the antitubercular drug bedaquiline, which inhibits ATP synthase in Mycobacterium tuberculosis. While work has been done to expand the success of bedaquiline to Gram-negative pathogens like AB through quinoline derivation, modifications to the quinoline core have been minimal. Herein, we report the synthesis and evaluation of a library of trisubstituted pyridines for their ability to inhibit AB ATP synthase and act as antibacterial agents against both susceptible and MDR AB clinical isolates. From this work, four lead compounds were developed that are highly potent and selective AB ATP synthase inhibitors and act as antibiotics against MDR AB. Additionally, each of the lead compounds were found to act synergistically with colistin against AB in bacterial culture, which demonstrates the further potential of this class to be developed into potent antibiotics.
pubs.acs.org
September 26, 2025 at 4:15 PM
Our drug discovery collaboration with the Wolfe Lab has received funding from NCInnovation for patent exploration. Patents are needed to advance the research, and external support is essential for small institutions like UNCA that do not have IP personnel in house.
ncinnovation.org/media/ncinno...
NCInnovation Approves $13.6 Million to Support 17 University R&D Projects - NCInnovation
Projects range from protecting agriculture and livestock to therapeutics for severe disease Research Triangle Park, NC – NCInnovation, a non-profit organization that helps unlock the innovative potent...
ncinnovation.org
May 22, 2025 at 12:11 PM
Dr. Steed also wrote a "behind the science" piece in the magazine ChemistryViews discussing the new paper. Find it here: doi.org/10.1002/chem...
New Quinoline Compounds Target Bacterial Energy Production - ChemistryViews
New Quinoline Compounds Target Bacterial Energy Production: Ryan Steed discusses their study on whether certain quinoline-based compounds can block the energy system of important antibiotic-resistant ...
doi.org
May 21, 2025 at 6:18 PM
We recently published a paper in collaboration with Amanda Wolfe's lab reporting quinoline compounds that inhibit ATP synthase and have antibacterial activity against the drug resistant pathogen Acinetobacter baumannii. Find it here: doi.org/10.1002/cmdc...
Quinoline ATP Synthase Inhibitors with Activity Against Multidrug Resistant Acinetobacter baumannii and Pseudomonas aeruginosa
Targeting ATP synthase in Gram-negative pathogens. Presented is the first disclosure of quinoline-derived antibiotics inhibiting multidrug resistant Acinetobacter baumannii ATP synthase and expansion...
doi.org
May 21, 2025 at 6:09 PM
Steed Lab is on Bluesky!
May 21, 2025 at 5:56 PM